Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
- 14 January 2013
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 19 (9) , 1175-1181
Abstract
Investigation of atrophy data from a pivotal natalizumab trial has demonstrated an increased rate of volume loss, compared to placebo, after the first year of therapy. It was considered to be probably due to a pseudoatrophy effect. To assess grey and white matter volume changes and their relation to global brain volume changes and to baseline inflammation, for patients under natalizumab therapy. We selected 45 patients on natalizumab therapy for at least 24 months, with magnetic resonance imaging (MRI) scans at baseline, 12 and 24 months. We calculated the percentage brain volume change (PBVC) for the first and second year, using SIENA software. Grey and white matter fractions (GMF and WMF, respectively) for the first year were calculated with SPM5, using lesion masks. After quality checks, six patients were excluded. We studied the predictive variables of change in brain volumes. The PBVC decrease was faster during the first year (−1.10% ± 1.43%), as compared to the second (−0.51% ± 0.96%) (p = 0.037). These differences were more marked in patients with baseline gadolinium-enhancing lesions (p = 0.005). Mean GMF and WMF changes during the first year of treatment were +1.15% (n.s.) and −1.72% (p = 0.017), respectively. The presence of active lesions at baseline MRI predicted PBVC (p = 0.022) and WMF change (p = 0.026) during the first year of treatment, after adjusting for age and corticosteroid treatment. No predictors were found for GMF volume changes. Early brain volume loss during natalizumab therapy is mainly due to WMF volume loss and it is related to the inflammatory activity present at the onset of therapy. We found that the pseudoatrophy effect is mostly due to white matter volume changes.Keywords
This publication has 26 references indexed in Scilit:
- Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosisMultiple Sclerosis Journal, 2011
- Three years of experience: the Italian registry and safety data updateNeurological Sciences, 2010
- Efficacy and tolerability of natalizumab in relapsing–remitting multiple sclerosis patients: a post-marketing observational studyNeurological Sciences, 2010
- Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in SwitzerlandEuropean Neurology, 2010
- Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countriesEuropean Journal of Neurology, 2009
- Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisNeurology, 2008
- I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophyMultiple Sclerosis Journal, 2007
- The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up studyJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Voxel-Based Morphometry—The MethodsNeuroImage, 2000
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998